Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The More Life CompanyTMLCF 3-Year EPS without NRI Growth Rate is 17.50% as of Mar. 2026, which is 30% below its 10-year median of 24.90. The stock has 3 warning signs investors should review. Among 785 Drug Manufacturers companies, The More Life Company ranks better than 63.44% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 17.50% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 21.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 7 years, the highest 3-Year average EPS without NRI Growth Rate of The More Life Company was 35.90% per year. The lowest was 0.00% per year. And the median was 24.90% per year.
The More Life Company (OTCPK:TMLCF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
The More Life Company 3-Year EPS without NRI Growth Rate Related Terms
TMLCF vs ZTS: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, The More Life Company's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The More Life Company 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, The More Life Company's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where The More Life Company's 3-Year EPS without NRI Growth Rate falls into.
The More Life Company 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 17.50% mean?
The More Life Company (TMLCF) has a 3-Year EPS without NRI Growth Rate of 17.50% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for The More Life Company and its competitors. This is 30% below median its historical median of 24.90. According to the industry distribution chart, The More Life Company ranks #287 out of 785 companies in the Drug Manufacturers industry, placing it in the top 36.6%.
Is The More Life Company's 3-Year EPS without NRI Growth Rate too high?
The More Life Company's current 3-Year EPS without NRI Growth Rate of 17.50% is 30% below median its 10-year median of 24.90. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.70. The More Life Company's value of 17.50% is 80.4% above this industry median. Based on the distribution chart, The More Life Company ranks #287 out of 785 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does The More Life Company's 3-Year EPS without NRI Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, The More Life Company ranks #287 out of 785 companies for 3-Year EPS without NRI Growth Rate. This puts The More Life Company in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 9.70. The More Life Company's value of 17.50% is 80.4% above this benchmark. While the company's 10-year median is 24.90 vs. the industry median of 9.70, The More Life Company has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.70, based on 785 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The More Life Company's current 3-Year EPS without NRI Growth Rate of 17.50% is 80.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for The More Life Company and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The More Life Company's current 3-Year EPS without NRI Growth Rate is 17.50%, which is 30% below median its own 10-year median of 24.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The More Life Company stock overvalued right now?
The More Life Company (TMLCF) has a current 3-Year EPS without NRI Growth Rate of 17.50%. The current 3-Year EPS without NRI Growth Rate is 17.50%, which is 30% below median its 10-year median of 24.90 and 80.4% above the Drug Manufacturers industry median of 9.70. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For The More Life Company (TMLCF), the current 3-Year EPS without NRI Growth Rate is 17.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mountain Valley MD Holdings Inc is a Canada-based company. The firm, along with its subsidiaries, is engaged in implementing its Quicksome oral delivery technologies across a variety of molecules in nutraceutical, vaccine, and pharmaceutical drug applications. The company actively invests in and collaborates on pioneering biotechnologies that have the potential to revolutionize the human health and wellness landscape, drive sustainable increases in plant yields and agricultural farming practices, and broadly support animal husbandry health. The Company is a biotech company focused on advancing solutions to optimize human, animal, and plant health.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TMLCF has been successfully added to your 
